PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to
the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer …

A hallmark of cancer is the ability of tumor cells to avoid immune destruction. Activated
immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and …

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

Abstract miRNA (miR) 34a has been shown to modulate critical gene transcripts involved in
tumorigenesis, but its role in tumor-mediated immunosuppression is largely unknown. PD …

In the last decades, many studies conducted in vitro, and in vivo, have shown that thyroid
autoimmunity and thyroid cancer (TC)(mainly papillary TC) can be concomitant, even if the …

The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Background Treatment options for advanced thyroid cancer refractory to standard therapies
are limited. The safety and efficacy of pembrolizumab were evaluated in patients with …

Abstract Programmed death-ligand 1 (PD-L1) expression on tumor cells is emerging as a
potential predictive biomarker in anti-PD-L1 directed cancer immunotherapy. We analyzed …

The programmed cell death protein 1 (PD-1) is expressed by activated T cells that act as an
immunoregulatory molecule, and are responsible for the negative regulation of T cell …

Several of the cancer immunotherapies under investigation or in clinical use target the
programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling axis. PD-L1 …